Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer
Webster EM, Zeybek B, Tymon-Rosario J, Santin AD. Sacituzumab govitecan: a promising antibody-drug conjugate for the treatment of poorly differentiated endometrial cancer. Oncoscience 2020, 7: 68-69. PMID: 33195736, PMCID: PMC7640901, DOI: 10.18632/oncoscience.514.Peer-Reviewed Original Research